Nicholas Stong

9PUBLICATIONS

77CO-AUTHORS

Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsGene mapping

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Jun 29, 2026

NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma.

|Jul 12, 2025

Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma.

Janek S Walker, Kerstin Wenzl, Joseph P Novak

|Aug 08, 2024

Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.

Matthew E Stokes, Kerstin Wenzl, C Chris Huang

|Nov 07, 2023

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.

Paola Neri, Benjamin G Barwick, David Jung

|Oct 12, 2022

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.

Naser Ansari-Pour, Mehmet Samur, Erin Flynt

|Aug 19, 2022

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic

Pageof 2

Frequent Collaborators

C Chris Huang

Thomas M Habermann

Matthew J Maurer

Anne J Novak

Erin Flynt

James R Cerhan

Stephen M Ansell

Anjan Thakurta

Fadi Towfic

Deborah S Mortensen

Frequent Collaborators

C Chris Huang

Thomas M Habermann

Matthew J Maurer

Anne J Novak